Journal Home
Search for

Volume 16, Issue 1, Pages 76-83 (January 2010)


View previous. 16 of 18 View next.

The Ventilatory Anaerobic Threshold in Heart Failure: A Multicenter Evaluation of Reliability

Jonathan Myers, PhD1Corresponding Author Informationemail address, Rochelle L. Goldsmith, PhD2, Steven J. Keteyian, PhD3, Clinton A. Brawner, MS3, Deirdre A. Brazil, BS2, Heather Aldred, PhD3, Jonathan K. Ehrman, PhD3, Daniel Burkhoff, MD2

Received 25 May 2009; received in revised form 7 July 2009; accepted 13 July 2009. published online 27 September 2009.

Abstract 

Background

The ventilatory threshold (VT) is usually determined by visual assessment of the point where the rate of elimination of carbon dioxide (VCO2) increases nonlinearly with respect to oxygen uptake (VO2) (the V-Slope method). We quantified the reliability of VT determination using data from a multicenter study in patients with heart failure.

Methods and Results

The Fix-Heart Failure-5 study of cardiac contractility modulation enrolled 428 patients from 50 centers in the United States. Cardiopulmonary exercise tests were performed at baseline and 12, 24, and 50 weeks after randomization, which provided 1679 tests. The VT was determined from each test in a core laboratory by 2 independent readers. VT could not be determined for 276 tests (16.4% indeterminate). Inter-observer variability (quantified by the 95% limits of agreement, LoA, expressed as a percent of the mean value) was 20.2% between the 2 readers, with a coefficient of variation (CV) of 7.3%. Intra-observer variability was assessed by resubmitting (blinded) 179 tests to the same readers; the LoA was 24.7% for reader 1 and 16.9% for reader 2, with CVs of 6.1 and 8.9%, respectively. Ninety-one tests were submitted to 2 additional readers at a second core lab. Inter-observer variability in the second lab was 26.7% with a CV of 9.6%. Inter-laboratory variability was 21.4%, with a CV of 7.7%.

Conclusions

Inter-observer, intra-observer, and inter-site variation in determining the VT should be considered when using the VT as an end point in clinical trials of heart failure.

1 VA Palo Alto Health Care System/Stanford University, Palo Alto CA

2 Columbia University, New York Presbyterian Medical Center, New York, NY

3 Henry Ford Hospital, Detroit, MI

Corresponding Author InformationReprint requests: Jonathan Myers, PhD, VA Palo Alto Health Care System, Cardiology 111C, 3801 Miranda Ave, Palo Alto CA 94304. Tel: (650) 493-5000 x64661; Fax: (650) 852-3473.

 The authors have no conflicts of interest.

PII: S1071-9164(09)00999-3

doi:10.1016/j.cardfail.2009.08.009


View previous. 16 of 18 View next.